Looking for the best size of instrumentation for vitrectomy
June 15th 2005La Jolla, CA—A 23-gauge vitrectomy should replace 20-gauge as the surgical standard because it offers benefits such as a small size, durability, and adaptability to any procedure without a learning curve, said Paul E. Tornambe, MD, one of only a handful of U.S. surgeons who regularly uses instruments of this size.
Auction raises funds for U.S. chapter
June 15th 2005Washington, DC—A silent auction of original paintings has helped to launch the American Friends of Vision for the World Inc., the U.S. chapter of a global non-profit organization dedicated to the prevention and curing of blindness in Third World countries.
Alcon may pay $95 million in dispute over phaco patents
June 15th 2005Santa Ana, CA—A jury has ordered Alcon Laboratories Inc. to pay Advanced Medical Optics Inc. (AMO) $94.8 million for what it found to be willful infringement of two patents for phacoemulsification equipment used during cataract surgery.
NIH initiatives driven by public health burden
June 15th 2005Fort Lauderdale, FL—The National Institutes of Health (NIH) is working to transform medicine in the 21st century in order to change the way it is practiced. The burden of public health has shifted from an acute to a chronic disease pattern, the population is aging rapidly, and the cost of healthcare is growing at an unprecedented rate.
Atypical mycobacteria drop, while gram-positive organisms rise
June 15th 2005Washington, DC—Results of the 2004 American Society of Cataract and Refractive Surgery (ASCRS) survey of infectious keratitis after refractive surgery show there has been an end to the epidemic of atypical mycobacterial infections.
CMS issues ruling on IOLs for presbyopia
June 15th 2005The Centers for Medicare &Medicaid Services (CMS) rulingon May 3 sets forth CMS policy concerning the requirements fordetermining payment for insertion of presbyopia-correcting IOLs following cataract surgery under thefollowing sections of the SocialSecurity Act (the Act):
Medicare patients can seek presbyopia-correcting IOLs
June 15th 2005Washington, DC—Medicare patients may now choose to pay extra to correct presbyopia with an IOL after cataract surgery under a new ruling by the Centers for Medicare & Medicaid Services (CMS), opening a vast, untapped market for IOL manufacturers and cataract surgeons.
Squalamine lactate preserves vision in phase II trial
June 1st 2005Key Biscayne, FL—In a small, phase II clinical trial of squalamine lactate (Evizon, Genaera Corp.), a systemically delivered drug for the treatment of choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD), all patients who received a 40-mg dose had preserved or improved vision through a 4-month study period, reported Carl Regillo, MD, FACS.
Clinical landscape of neovascular AMD is changing
June 1st 2005In the world of eye care, therapy for age-related macular degeneration (AMD) presents as an urgent medical need both now and for future generations. Neovascular AMD accounts for 20% of total AMD cases, but 90% of the severe loss of vision that is associated with the disease, and there are more than 200,000 new cases of neovascular AMD each year.
Transient monocular visual loss exam must be thorough
June 1st 2005Salt Lake City—Transient monocular visual loss, amaurosis fugax, is a common complaint that ophthalmologists encounter. The challenge for the ophthalmologist is to determine if the cause is benign or of a more serious vascular origin. Kathleen Digre, MD, described the step-by-step approach to discovering the answer.
Know what to look for in the case of AVMs
June 1st 2005New York—Some cerebrovascular events, such as arteriovenous malformations (AVMs) and aneurysms of the brain, occur far less often than migraines and strokes but nevertheless may present in the ophthalmologist's office. With this type of pathology that has ocular manifestations, the ophthalmologist may be one of the first specialists to examine the patient, and knowing what to look for is of paramount importance.
Ophthalmologist travels to Zambia to help those in need
June 1st 2005As physicians, my wife and I spent 2 weeks in Zambia with a group of 20 other professionals from the United States and United Kingdom. The expertise included banking, foundation management, real estate development, teaching, communications, and medicine.
TASS may be effect of cataract/anterior segment surgery
June 1st 2005Salt Lake City—Toxic anterior segment syndrome (TASS) is an acute noninfectious inflammatory event that usually occurs within 12 to 24 hours following cataract/ anterior segment surgery. Surgeons need to differentiate between TASS and endophthalmitis and carefully determine the cause of the syndrome, according to Nick Mamalis, MD.
More surgeons adopting 25-gauge vitrectomy technique
June 1st 2005Minimally invasive, sutureless, 25-gauge vitrectomy has been an option for only a few years but appears to be gaining converts, although with widespread acknowledgment that the system has limitations when compared with the well-established 20-gauge technology.
Interim results favorable for dye-enhanced feeder vessel treatment
June 1st 2005Key Biscayne, FL—Preliminary analyses from a phase II study demonstrate the feasibility of dye-enhanced photocoagulation (DEP) feeder vessel treatment (FVT) in eyes with minimally classic choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD). This new technique may have benefits compared with laser photocoagulation FVT alone for both increasing the efficiency of the procedure and allowing for treatment of larger diameter vessels, said Giovanni Staurenghi, MD, at the annual meeting of the Macula Society.
Baseline vision influences role of submacular surgery in NIH-sponsored trial
June 1st 2005Baltimore—Results from the Group H Submacular Surgery Trial (SST), sponsored by the National Eye Institute of the National Institutes of Health (NIH), support consideration of surgical removal of subfoveal choroidal neovascularization (CNV) in eyes with poorer vision as measured in the SST and vessel growth that is idiopathic or associated with the ocular histoplasmosis syndrome, said Neil M. Bressler, MD, at the Current Concepts in Ophthalmology meeting.
Counter pressure device 100% effective in controlling drug reflux
June 1st 2005Tucson, AZ—Use of a counter-pressure device (CPD) during the posterior juxtascleral administration of anecortave acetate for depot suspension (Retaane, Alcon Laboratories) effectively eliminates reflux to ensure consistent drug delivery, according to the results of a clinical pharmacokinetics study.
Squalamine lactate preserves vision in phase II trial
June 1st 2005Key Biscayne, FL—In a small, phase II clinical trial of squalamine lactate (Evizon, Genaera Corp.), a systemically delivered drug for the treatment of choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD), all patients who received a 40-mg dose had preserved or improved vision through a 4-month study period, reported Carl Regillo, MD, FACS.